Polaris Group (TPE:6550)

Market Cap	18.57B -51.1%
Revenue (ttm)	40.60M -6.4%
Net Income	-3.93B
EPS	-5.10
Shares Out	770.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	992,314
Average Volume	1,640,435
Open	24.10
Previous Close	26.75
Day's Range	24.10 - 24.10
52-Week Range	24.10 - 46.50
Beta	0.48
RSI	30.53
Earnings Date	Mar 18, 2026

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Grand Cayman.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 165
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6550

Financial Performance

In 2024, Polaris Group's revenue was 107.00 million, an increase of 1330.29% compared to the previous year's 7.48 million. Losses were -2.50 billion, 67.7% more than in 2023.